{
    "clinical_study": {
        "@rank": "37082", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if intravenous BCX-1777 can be given safely to\n      improve relapsed or refractory aggressive T-cell leukemias and lymphomas."
        }, 
        "brief_title": "Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas", 
        "completion_date": "March 2004", 
        "condition": [
            "Leukemia, Lymphocytic", 
            "Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphoid", 
                "Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Despite the great strides that have been made in improving the outcome with frontline\n      programs of intensive chemotherapy in patients with aggressive T-cell malignancies, the\n      prognosis with relapsed or refractory T-cell leukemias or lymphomas is poor. BCX-1777 is a\n      purine nucleoside phosphorylase (PNP) inhibitor and a potential T-cell target therapy.\n\n      The purpose of the phase I portion of the study is to  determine the maximum tolerated dose\n      (MTD) of BCX-1777 and the dose to be studied in the phase II portion of the study.\n\n      The purpose of the phase II portion of the study is to determine the safety and efficacy of\n      BCX-1777 in patients with relapsed or refractory aggressive T-cell malignancies.\n\n      Patients who respond to BCX-1777 or have stable disease may be eligible to receive an\n      additional course of treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previously treated, relapsed or refractory aggressive T-cell malignancies (leukemias\n             and lymphomas) histologically proven with measurable disease.\n\n          -  Capable of only limited self-care, confined to bed or chair more than 50% of waking\n             hours.\n\n          -  All ages are eligible.  Pediatric patients (<15 years of age) are eligible to be\n             treated at a dose level previously tested in adults.\n\n          -  Adequate liver and renal function.\n\n          -  Patients with prior history of stem cell transplant if they meet all other\n             eligibility requirements.\n\n          -  Negative pregnancy test within 72 hours of study treatment in females of childbearing\n             potential.\n\n          -  Life expectancy of at least 2 months.\n\n        Exclusion:\n\n          -  Active serious infection not controlled by oral or intravenous antibiotics.\n\n          -  Treatment with any investigational antileukemic agents or chemotherapy agents in the\n             last 7 days before study entry, unless full recovery from side-effects has occurred\n             or patient has rapidly progressive disease judged to be life-threatening by the\n             investigator.\n\n          -  Concurrent treatment with other anti-cancer agents.\n\n          -  Known CNS leukemia or lymphoma requiring intrathecal or craniospinal radiation\n             therapy.  Lumbar puncture not required in asymptomatic patients.\n\n          -  Pregnant and/or lactating women; or fertile men or women not willing to use\n             contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "71", 
        "firstreceived_date": "May 2, 2002", 
        "id_info": {
            "nct_alias": "NCT00066235", 
            "nct_id": "NCT00035022", 
            "org_study_id": "BC-01-02"
        }, 
        "intervention": {
            "intervention_name": "BCX-1777", 
            "intervention_type": "Drug"
        }, 
        "keyword": "Leukemia, Lymphoma, T-Cell", 
        "lastchanged_date": "January 12, 2006", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "M.D. Anderson Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase I-II Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive (High Grade) T-Cell Malignancies", 
        "overall_official": {
            "affiliation": "M.D. Anderson Cancer Center", 
            "last_name": "Deborah A. Thomas, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00035022"
        }, 
        "source": "BioCryst Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioCryst Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2001", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2005"
    }, 
    "geocoordinates": {
        "M.D. Anderson Cancer Center": "29.76 -95.369"
    }
}